Application of ProTide technology to gemcitabine: A successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1531-1542

  Slusarczyk, Magdalena ^a   Lopez, Monica Huerta ^a   Balzarini, Jan ^b   Mason, Malcolm ^c   Jiang, Wen G ^d   Blagden, Sarah ^e   Thompson, Emely ^f   Ghazaly, Essam ^f   McGuigan, Christopher ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; GEMCITABINE; NUC 1031; NUCLEOSIDE ANALOG; NUCLEOSIDE TRANSPORTER; PHOSPHORAMIDIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOSTASIS; DOG; DRUG DEGRADATION; DRUG POTENCY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; RAT; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CYTIDINE MONOPHOSPHATE; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 84896827026     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401853a     Document Type: Article

References (56)

1. Hertel, L. W.; Kroin, J. S.; Misner, J. W.; Tustin, J. M. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2′-deoxy-2′,2′-difluoro-D- ribofuranosyl nucleosides J. Org. Chem. 1988, 53, 2406-2409
2. Hertel, L. W.; Boder, G. B.; Kroin, J. S.; Rinzel, S. M.; Poore, G. A.; Todd, G. C.; Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) Cancer Res. 1990, 50, 4417-4422
3. Braakhuis, B. J.; Ruiz van Haperen, V. W.; Welters, M. J.; Peters, G. J. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts Eur. J. Cancer 1995, 31A, 2335-2340
4. Merriman, R. L.; Hertel, L. W.; Schultz, R. M.; Houghton, P. J.; Houghton, J. A.; Rutherford, P. G.; Tanzer, L. R.; Boder, G. B.; Grindey, G. B. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models Invest. New Drugs 1996, 14, 243-247
5. Manegold, C. Gemcitabine (Gemzar) in non-small cell lung cancer Expert Rev. Anticancer Ther. 2004, 4, 345-360
6. Heinemann, V. Gemcitabine in metastatic breast cancer Expert Rev. Anticancer Ther. 2005, 5, 429-443
7. Eckel, F.; Schneider, G.; Schmid, R. M. Pancreatic cancer: a review of recent advances Expert Opin. Invest. Drugs 2006, 15, 1395-1410
8. Toschi, L.; Finocchiaro, G.; Bartolini, S.; Gioia, V.; Cappuzzo, F. Role of gemcitabine in cancer therapy Future Oncol. 2005, 1, 7-17
9. Huang, P.; Chubb, S.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res. 1991, 51, 6110-6117
10. Ruiz van Haperen, V. W.; Veerman, G.; Vermorken, J. B.; Peters, G. J. 2′,2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines Biochem. Pharmacol. 1993, 46, 762-766
11. Heinemann, V.; Xu, Y. Z.; Chubb, S.; Sen, A.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Cellular elimination of 2′,2′- difluorodeoxycytidine-5′-triphosphate: a mechanism of self-potentiation Cancer Res. 1992, 52, 533-539
12. Ruiz van Haperen, V. W.; Veerman, G.; Eriksson, S.; Boven, E.; Stegmann, A. P.; Hermsen, M.; Vermorken, J. B.; Pinedo, H. M.; Peters, G. J. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine- resistant variant of the human ovarian carcinoma cell line A2780 Cancer Res. 1994, 54, 4138-4143
13. Kroep, J. R.; Loves, W. J.; van der Wilt, C. L.; Alvarez, E.; Talianidis, I.; Boven, E.; Braakhuis, B. J. M.; van Groeningen, C. J.; Pinedo, H. M.; Peters, G. J. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity Mol. Cancer Ther. 2002, 1, 371-376
14. Galmarini, C. M.; Clarke, M. L.; Jordheim, L.; Santos, C. L.; Cros, E.; Mackey, J. R.; Dumontet, C. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene BMC Pharmacol. 2004, 4, 8
15. Heinemann, V.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine Cancer Res. 1988, 48, 4024-4031
16. Gandhi, V.; Plunkett, W. Modulatory activity of 2′,2′- difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides Cancer Res. 1990, 50, 3675-3680
17. Beumer, J. H.; Eiseman, J. L.; Parise, R. A.; Joseph, E.; Covey, J. M.; Egorin, M. J. Modulation of gemcitabine (2′,2′-difluoro-2′- deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine Clin. Cancer Res. 2008, 14, 3529-3535
18. Mini, E.; Nobili, S.; Caciagli, B.; Landini, I.; Mazzei, T. Cellular pharmacology of gemcitabine Ann Oncol. 2006, 17 (Suppl 5) v 7-12
19. Mackey, J. R.; Mani, R. S.; Selner, M.; Mowles, D.; Young, J. D.; Belt, J. A.; Crawford, C. R.; Cass, C. E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res. 1998, 58, 4349-4357
20. Gourdeau, H.; Clarke, M. L.; Ouellet, F.; Mowles, D.; Selner, M.; Richard, A.; Lee, N.; Mackey, J. R.; Young, J. D.; Jolivet, J.; Lafrenière, R. G.; Cass, C. E. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines Cancer Res. 2001, 61, 7217-7224
21. www.GEMZAR.com. Locally advanced or metastatic pancreatic cancer.
22. Liau, S.-S.; Whang, E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma Clin. Cancer Res. 2008, 14, 1470-1477
23. Moysan, E.; Bastiat, G.; Benoit, J. P. Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications Mol. Pharmaceutics 2013, 10, 430-444
24. Bender, D. M.; Bao, J.; Dantzig, A. H.; Diseroad, W. D.; Law, K. L.; Magnus, N. A.; Peterson, J. A.; Perkins, E. J.; Pu, Y. J.; Reutzel-Edens, S. M.; Remick, D. M.; Starling, J. J.; Stephenson, G. A.; Vaid, R. K.; Zhang, D.; McCarthy, J. R. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine J. Med. Chem. 2009, 52, 6958-6961
25. Koolen, S. L. W.; Witteveen, P. O.; Jansen, R. S.; Langenberg, M. H. G.; Kronemeijer, R. H.; Nol, A.; Garcia-Ribas, I.; Callies, S.; Benhadji, K. A.; Slapak, C. A.; Beijnen, J. H.; Voest, E. E.; Schellens, J. H. M. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors Clin. Cancer Res. 2011, 17, 6071-6082
26. Bergman, A. M.; Adema, A. D.; Balzarini, J.; Bruheim, S.; Fichtner, I.; Noordhuis, P.; Fodstad, O.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Peters, G. J. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models Invest. New Drugs 2011, 29, 456-466
27. Adema, A. D.; Smid, K.; Losekoot, N.; Honeywell, R. J.; Verheul, H. M.; Myhren, F.; Sandvold, M. L.; Peters, G. J. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126 Invest. New Drugs 2012, 30, 1908-1916
28. Ahmed, T. Clavis and Clovis collaborate on anticancer drug CP-4126. Pharma Deals Review 2009, 12, 122. In 2012, Clavis Pharma and Clovis Oncology suspended further development of CP-4126 after demonstrating no difference in overall survival between CP-4126 and gemcitabine in hENT1-low patients.
29. Bazzanini, R.; Manfredini, S.; Durini, E.; Gröschel, B.; Cinatl, J.; Balzarini, J.; De Clercq, E.; Imbach, J. L.; Péirgaud, C.; Gosselin, G. Prodrugs of Ara-CMP and Ara-AMP with a S-acyl-2-thioethyl (SATE) biolabile phosphate protecting group: synthesis and biological evaluation Nucleoside Nucleotides 1999, 18, 971-972
30. Galmarini, C. M.; Warren, G.; Senanayake, M. T.; Vinogradov, S. V. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs Int. J. Pharm. 2010, 395, 281-289
31. Cahard, D.; McGuigan, C.; Balzarini, J. Aryloxy phosphoramidate triesters as protides Mini-Rev. Med. Chem. 2004, 4, 371-381
32. McGuigan, C.; Shackleton, J. M.; Tollerfield, S. M.; Riley, P. A. Synthesis and evaluation of some novel phosphate and phosphinate derivatives of araA. Studies on the mechanism of action of phosphate triesters Nucleic Acids Res. 1989, 17, 10171-10177
33. Balzarini, J.; Karlsson, A.; Aquaro, S.; Perno, C. F.; Cahard, D.; Naesens, L.; De Clercq, E.; McGuigan, C. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 7295-7299
34. McGuigan, C.; Harris, S. A.; Daluge, S. M.; Gudmundsson, K. S.; McLean, E. W.; Burnette, T. C.; Marr, H.; Hazen, R.; Condreay, L. D.; Johnson, L.; De Clercq, E.; Balzarini, J. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency J. Med. Chem. 2005, 48, 3504-3515
35. Vernachio, J. H.; Bleiman, B.; Bryant, K. D.; Chamberlain, S.; Hunley, D.; Hutchins, J.; Ames, B.; Gorovits, E.; Ganguly, B.; Hall, A.; Kolykhalov, A.; Liu, Y.; Muhammad, J.; Raja, N.; Walters, C. R.; Wang, J.; Williams, K.; Patti, J. M.; Henson, G.; Madela, K.; Aljarah, M.; Gilles, A.; McGuigan, C. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties Antimicrob. Agents Chemother. 2011, 55, 1843-1851
36. Walsby, E.; Congiatu, C.; Schwappach, A.; Walsh, V.; Burnett, A. K.; McGuigan, C.; Mills, K. I. Nucleoside analogues of cladribine produce enhanced responses in cell lines Blood 2005, 106, 941A-942A (Abstract 3369).
37. McGuigan, C.; Congiatu, C.; Mills, K. Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer. EP1866324A1, WO 2006100439 A1.
38. Vande Voorde, J.; Liekens, S.; McGuigan, C.; Murziani, P. G. S; Slusarczyk, M.; Balzarini, J. The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2′-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes Biochem. Pharmacol. 2011, 82, 441-452
39. McGuigan, C.; Murziani, P. G. S.; Slusarczyk, M.; Gonczy, B.; Vande Voorde, J.; Liekens, S.; Balzarini, J. Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside J. Med. Chem. 2011, 54, 7247-7258
40. McGuigan, C. Preparation of amino acid-containing nucleotide phosphoramidates as antitumor agents. PCT. Int. Appl. 2005, WO 2005012327 A2 20050210.
41. McGuigan, C. Nucleotide phosphoramidates as anticancer agents. US 7951787 B2, 2005.
42. Ghazaly, E. A; Simon, J.; Gribben, J. G.; Mohammad, T.; Oluwadunni, E.; Stavraka, Ch.; Hopkins, T.; Gabra, H.; Harpreet, W.; Habib, N. A.; Leonard, R. C. F.; McGuigan, C.; Slusarczyk, M.; Blagden, S. P. ProGem1: Phase 1 first-in-human study of the novel nucleotide analogue NUC-1031 in adult patients with advanced solid tumors. 2013 ASCO Annual Meeting J. Clin. Oncol. 2013, 31 (suppl; Abstract 2576).
43. Guo, Z.; Gallo, J. M. Selective protection of 2′,2′- difluorodeoxycytidine (Gemcitabine) J. Org. Chem. 1999, 64, 8319-8322
44. McGuigan, C.; Pathirana, R. N.; Balzarini, J.; De Clercq, E. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT J. Med. Chem. 1993, 36, 1048-1052
45. Greene, T. W.; Wuts, P. G. M. Protective groups, in Organic Chemistry, 2 nd ed.; Wiley: New York, 1991.
46. Curley, D.; McGuigan, C.; Devine, K. G.; O'Connor, T. J.; Jeffries, D. J.; Kinchington, D. Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of AZT: studies on the effect of chain elongation on biological activity Antiviral Res. 1990, 14, 345-356
47. McGuigan, C.; Devine, K. G.; O'Connor, T. J.; Kinchington, D. Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3′-azido-3′-deoxythymidine (AZT): potent activity of the trichloroethyl methoxyalaninyl compound Antiviral Res. 1991, 15, 255-263
48. Saboulard, D.; Naesens, L.; Cahard, D.; Salgado, A.; Pathirana, R.; Velazquez, S.; McGuigan, C.; De Clercq, E.; Balzarini, J. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine Mol. Pharmacol. 1999, 56, 693-704
49. Birkus, G.; Wang, R.; Liu, X.; Kutty, N.; MacArthur, H.; Cihlar, T.; Gibbs, C.; Swaminathan, S.; Lee, W.; McDermott, M. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131 Antimicrob. Agents Chemother. 2007, 51, 543-550
50. Bengala, C.; Guarneri, V.; Giovannetti, E.; Lencioni, M.; Fontana, E.; Mey, V.; Fontana, A.; Boggi, U.; Del Chiaro, M.; Danesi, R.; Ricci, S.; Mosca, F.; Del Tacca, M.; Conte, P. F. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma Brit. J. Cancer. 2005, 93, 35-40
51. Camiener, G. W. Studies of the enzymatic deamination of cytosine arabinoside. 3. Substrate requirements and inhibitors of the deaminase of human liver Biochem. Pharmacol. 1967, 16, 1691-1702
52. Song, X.; Lorenzi, P. L.; Landowski, C. P.; Vig, B. S.; Hilfinger, J. M.; Amidon, G. L. Amino acid ester prodrugs of the anticancer agents gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport Mol. Pharm. 2005, 2, 157-167
53. Li, A. P.; Lu, C.; Brent, J. A.; Pham, C.; Fackett, A.; Ruegg, C. E.; Silber, P. M. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential Chem. Biol. Interact. 1999, 121, 17-35
54. Kuhnz, W.; Gieschen, H. Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro Drug Metab. Dispos. 1998, 26, 1120-1127
55. Murakami, E.; Niu, C.; Bao, H.; Micolochick Steuer, H. M.; Whitaker, T.; Nachman, T.; Sofia, M. A.; Wang, P.; Otto, M. J.; Furman, P. A. The mechanism of action of ß-D-2′-deoxy-2′-fluoro-2′- C -methylcytidine involves a second metabolic pathway leading to ß-D-2′-deoxy- 2′-fluoro-2′- C -methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase Antimicrob. Agents Chemeother. 2008, 52, 458-464
56. CDA Activity Assay, Material Safety Datasheets available at www.acris-antibodies.com.